SCHEMBL3364896

SCHEMBL3364896

COC(=O)CNC(Cc1ccccc1)C(=O)OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
ALDH1A1 P00352 2/20 0.56
THRB P10828 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
HSD17B10 Q99714 1/20 0.56
POLB P06746 2/20 0.55
CA12 O43570 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
LMNA P02545 1/20 0.52
GLA P06280 1/20 0.52
ANPEP P15144 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GAA P10253 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2896038 0.90 MEN1 (0.57) ATMMEN1KMT2AALDH1A1THRB
SCHEMBL2896037 0.90 MEN1 (0.57) ATMMEN1KMT2AALDH1A1THRB
SCHEMBL8922417 0.89 ATM (0.58) ATMMEN1KMT2AALDH1A1THRB
SCHEMBL7434834 0.89 ATM (0.58) ATMMEN1KMT2AALDH1A1THRB
SCHEMBL30823314 0.88 PPARG (0.60) MEN1KMT2AALDH1A1LMNAGAA
SCHEMBL27136481 0.88 PPARG (0.60) MEN1KMT2AALDH1A1LMNAGAA
SCHEMBL4022466 0.87 ITGA4 (0.58) ATMMEN1KMT2AALDH1A1THRB
SCHEMBL4022463 0.87 ITGA4 (0.58) ATMMEN1KMT2AALDH1A1THRB
SCHEMBL6440329 0.87 ITGA4 (0.58) ATMMEN1KMT2AALDH1A1THRB
SCHEMBL19647162 0.87 ALDH1A1 (0.62) ATMMEN1KMT2AALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100124702-A1 High Energy Composite Cathodes for Lithium Ion Batteries PHYSICAL SCIENCES, INC. (US) 2010-05-20 US disclosed
US-7279576-B2 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-10-09 US disclosed
EP-1590344-A4 ANTI-CANCER MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2007-08-29 EP disclosed
EP-1590344-A2 ANTI-CANCER MEDICAMENTS Deciphera Pharmaceuticals, Inc. (US) 2005-11-02 EP disclosed
US-20040176395-A1 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC 2004-09-09 US disclosed
WO-2004060305-A2 ANTI-CANCER MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176395-A1 Anti-cancer medicaments ABL1, ABL2, SRC ATM 955/4885MEN1 3885/4885KMT2A 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.